Dr Cameron Curley describes CAR T-cell therapy as “arguably the biggest breakthrough in the treatment of many blood cancers in the last decade”.
A clinical trial, due to open in mid-2022, will give young people access to two promising new ALL drugs.
Find out why the clinical haematologist is dedicating his life to CLL.
Ciltacabtagene autoleucel (cilta-cel), is being appraised by the Medical Services Advisory Committee (MSAC) for listing on the Medicare Benefits Schedule.
It’s emerging in all cancers, but particularly in the MPNs, that “genomics is everything” according to Professor Andrew Perkins, an expert in myeloproliferative neoplasms (MPN).
In a first-ever Australian-French collaboration, an exciting new clinical trial, due to open before Christmas, will give Australians with relapsed or refractory AL amyloidosis access to a new drug combination.
Dr Pagani has a vision for a personalised approach to treatment-free remission in CML
Newly revised optimal care pathways (OCPs) provide best practice information for the treatment and care of people living with acute myeloid leukaemia (AML), and diffuse large B-cell lymphoma (DLBCL) and Hodgkin lymphoma (HL).
